| answer text |
<p>The Prime Minister has made clear that a key priority through the negotiations
will be to ensure that the United Kingdom remains one of the best places in the world
for science and innovation. In the negotiations, the Government will discuss with
the European Union and Member States how best to continue cooperation in the field
of medicines regulation in the best interests of both the UK and the EU. Our aim is
to ensure that patients in the UK and across the EU continue to be able to access
the best and most innovative medicines and be assured that their safety is protected
through the strongest regulatory framework and sharing of data.</p><p> </p><p>In the
UK, the Medicines and Healthcare products Regulatory Agency, Health Research Authority,
ethics services, National Institute for Health Research and the National Health Service
have been working towards implementation of the new European Clinical Trials Regulation
(CTR) since it was agreed in 2014. The application date of the CTR across the EU will
be set by the European Commission. The current regulatory approval legislation will
stay in place until such time as any changes are needed so there will be no interruption
in UK clinical trials approval.</p>
|
|
